| For immediate release | 5 April 2024 |
ALLIANCE PHARMA
("Alliance", "Company" or the "Group")
Update on timing of preliminary results announcement
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the preliminary results for 2023 are now expected to be published on 23 April 2024. The Group's auditor has determined that the volume of work required to complete the audit has exceeded its original expectations, necessitating a short delay in the reporting timetable.
Alliance confirms that the details provided in the full year trading update on 29 January 2024 remain accurate.
A meeting for analysts will be held at 9.30am on the day of the results at Buchanan, 107 Cheapside, London. Details of the live webcast of the meeting will be provided shortly in the investor section of the Alliance website, https://www.alliancepharmaceuticals.com/investors, where a replay will also be made available following the meeting.
For further information:
| Alliance Pharma plc | + 44 (0)1249 466966 |
| Cora McCallum, Head of Investor Relations & Corporate Communications | + 44 (0)1249 705168 |
|
| |
|
|
|
| Buchanan | + 44 (0)20 7466 5000 |
| Mark Court / Sophie Wills |
|
|
| |
|
|
|
| Deutsche Numis (Nominated Adviser and Joint Broker) | + 44 (0)20 7260 1000 |
| Freddie Barnfield / Duncan Monteith / Sher Shah |
|
|
|
|
| Investec Bank plc (Joint Broker) | + 44 (0)20 7597 5970 |
| Patrick Robb / Maria Gomez de Olea |
|
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.